Understand the question
Hormone advice can become outdated when it repeats an old safety warning or interprets a regulatory change too broadly. The useful approach is to identify exactly what changed, what evidence prompted it, and which population the information concerns. A headline about testosterone should not be turned into a recommendation for every person who wants more energy.
In February 2025, the FDA announced testosterone labeling changes informed by the TRAVERSE trial and blood-pressure studies. The changes included removing boxed-warning language about increased adverse cardiovascular outcomes and requiring information about increased blood pressure. A change to one warning does not mean a treatment has no risks or is appropriate for every proposed use.
A practical way to evaluate it
In April 2026, the FDA invited sponsors to discuss a potential new indication for low libido in men with idiopathic hypogonadism. The announcement described a possible application pathway and the need for adequate evidence. It should not be reported as an approval of that proposed indication or as authorization for general anti-aging treatment. The exact current product label and clinical circumstances remain important.
When discussing treatment, bring the particular product and proposed purpose into the conversation. Ask how benefit would be assessed, what monitoring is planned, and what would prompt reconsideration. Do not obtain a regimen from an enhancement article or use someone else’s result as a personal prediction. Regulatory updates help improve the questions you ask; they do not replace individualized medical evaluation or turn an uncertain symptom into a diagnosis.
Sources & further reading
- FDA: Class-wide labeling changes for testosterone products, February 2025www.fda.gov
- FDA: Step forward on testosterone therapy for menwww.fda.gov